New York, NYNCT07213960Now EnrollingIRB Ready

FSGS Clinical Trial in New York, NY

Access cutting-edge fsgs treatment through this phase 2/3 clinical trial at a research site in New York. Study-provided care at no cost to qualified participants.

Sponsored by Apellis Pharmaceuticals, Inc.

Quick Self-Assessment

See if you qualify for this New York location

Preparing your pre-screening questions…

Expert Care in New York

Access fsgs specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related fsgs treatment provided free

Apply for This New York Location

Check if you qualify for this fsgs clinical trial in New York, NY

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to New York

    Convenient for NY residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit New York site if eligible
  4. 4Begin participation

About This FSGS Study in New York

This is a sequential phase 2/3 study to evaluate the efficacy and safety of twice-weekly subcutaneous (SC) infusions of APL2 in patients diagnosed with FSGS. The initial phase 2 portion is a single-arm, open-label study in adults diagnosed with FSGS. Phase 2 will commence prior to randomizing for phase 3. The phase 3 portion of the study is a randomized, placebo-controlled, double-blinded, multicenter study in adults and adolescents diagnosed with FSGS.

Sponsor: Apellis Pharmaceuticals, Inc.

Who Can Participate

Inclusion Criteria

Phase 2: adults aged ≥18 years
Phase 3: adults aged ≥18 years; if and where approved, adolescents (aged 12--17 years) at the time of signing the informed consent and assent form
Weight ≥30 kg and ≤100 kg at screening
FSGS diagnosis
Phase 2: primary, genetic, or undetermined FSGS diagnosed by kidney biopsy
Phase 3: primary, genetic, or undetermined FSGS diagnosed by kidney biopsy or by recognized podocyte genetic mutation
At least 1.5 g/day of proteinuria on a screening 24-hour urine collection and a uPCR of at least 1.5 g/g in at least 2 FMU samples collected during screening
Estimated glomerular filtration rate (eGFR) ≥25 mL/min/1.73 m2
Stable regimen for FSGS treatment for at least 12 weeks prior to randomization, with no planned or anticipated adjustments or dose changes to the stable treatment regimen

Exclusion Criteria

Previous exposure to APL2
Evidence of improving kidney disease in the 8 weeks prior to screening or during the screening period according to available data
FSGS secondary to another condition (eg, infectious, diabetic, drug-induced, obesity, prematurity, sickle-cell, vesicoureteral reflux, congenital anomalies of the kidney, and urinary tract)
Type 1 or uncontrolled (HbA1C ≥8%) type 2 diabetes mellitus
History of kidney transplant
Current or prior diagnosis of HIV, hepatitis B, or hepatitis C infection or positive serology or viral load during screening that is indicative of active infection with any of these viruses
Hypersensitivity to APL2 or to any of the excipients
Significant other kidney disease that would, in the opinion of the investigator, confound interpretation of study results
Use of rituximab, belimumab, or any approved or investigational anticomplement therapy within 5 half-lives of that product prior to the screening period

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in New York?

Yes, this clinical trial (NCT07213960) has an active research site in New York, NY that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

FSGS Treatment Options in New York, NY

If you're searching for fsgs treatment options in New York, NY, this clinical trial (NCT07213960) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our New York research site is actively enrolling participants for this phase 2/3 clinical trial. You'll receive care from experienced fsgs specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all fsgs clinical trials near you to find additional studies recruiting in your area.

More Nephrotic Syndrome Trials in New York, NY

See all nephrotic syndrome clinical trials recruiting in New York — not just this study.

Browse Nephrotic Syndrome Trials in New York →

Browse More Trials by Condition

Nephrotic Syndrome TrialsAll Conditions →

Ready to Join in New York?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · New York, NY